BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35544739)

  • 21. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
    Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
    Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
    Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
    Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
    Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
    Krapf MK; Gallus J; Namasivayam V; Wiese M
    J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
    Zhang H; Zhang YK; Wang YJ; Kathawala RJ; Patel A; Zhu H; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Fu LW
    Cancer Sci; 2014 Aug; 105(8):1071-8. PubMed ID: 24903205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
    Nakanishi T; Ross DD
    Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
    Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
    PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
    Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.